Recently, everolimus with exemestane (EVE/EXE) has been registered for treatment for patients with estrogen receptor (ER)‐positive, human epidermal growth factor receptor type 2 (HER2)‐negative metastatic breast cancer (MBC) to prevent cancer cell survival caused by an activated PI3K pathway (Zoncu et al., 2011). Here, ESR1 is linked to cancer.